1.

Chen MS, Wang SF, Hsu CY, Yin PH, Yeh TS, Lee HC*, Tseng LM*.  CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2α-ATF4 pathway.  Oncotarget. 2017 Dec 9;8(70):114588-114602. doi: 10.18632/oncotarget.23055. eCollection 2017 Dec 29. (I F=5.008；R/C=36/213，Oncology，2016)

2.

Liu CY, Lau KY, Hsu CC, Chen JL, Lee CH, Huang TT, Chen YT, Huang CT, Lin PH, Tseng LM*.  Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.  PLoS One. 2017 Dec 20;12(12):e0189007. doi: 10.1371/journal.pone.0189007. eCollection 2017. (IF=2.806, 15/64, MULTIDISCIPLINARY SCIENCES E, 2016)

3.

Sung PL, Wen KC, Chen YJ, Chao TC, Tsai YF, Tseng LM, Qiu JT, Chao KC, Wu HH, Chuang CM, Wang PH, Huang CF.  The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.  PLoS One. 2017 Sep 29;12(9):e0185615. doi: 10.1371/journal.pone.0185615. eCollection 2017. (IF=2.806, 15/64, MULTIDISCIPLINARY SCIENCES E, 2016)

4.

Liu CY, Wu CY, Petrossian K, Huang TT, Tseng LM, Chen S.  Treatment for the endocrine resistant breast cancer: Current options and future perspectives.  J Steroid Biochem Mol Biol. 2017 Sep;172:166-175. (I F=4.561；R/C=60/290，BIOCHEMISTRY & MOLECULAR BIOLOGY，2016)

5.

Chiu JH, Chen FP, Tsai YF, Lin MT, Tseng LM*, Shyr YM.  Effects of Chinese medicinal herbs on expression of brain-derived Neurotrophic factor (BDNF) and its interaction with human breast cancer MDA-MB-231 cells and endothelial HUVECs.  BMC Complement Altern Med. 2017 Aug 12;17(1):401. (IF=2.288, 6/26, INTEGRATIVE & COMPLEMENTARY MEDICINE, 2016)

6.

Liu CY, Huang TT, Chu PY, Huang CT, Lee CH, Wang WL, Lau KY, Tsai WC, Chao TI, Su JC, Chen MH, Shiau CW, Tseng LM*, Chen KF.  The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.   Exp Mol Med. 2017 Aug 11;49(8):e366  (IF=5.063, 13/128, MEDICINE, RESEARCH & EXPERIMENTAL, 2016)

7.

Tsai YF, Tseng LM*, Hsu CY, Yang MH, Chiu JH*, Shyr YM.  Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer.  PLoS One. 2017 Jun 12;12(6):e0178173. doi:10.1371/journal.pone.

0178173.  eCollection 2017. (IF=2.806, 15/64, MULTIDISCIPLINARY SCIENCES E, 2016)

8.

Chen PM, Chu PY, Tung SL, Liu CY, Tsai YF, Lin YS, Wang WL, Wang YL, Lien PJ, Chao TC, Tseng LM*.  Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.    Hum Pathol. 2017 Jun 8. pii: S0046-8177(17)30215-0. doi: 10.1016/j.humpath.2017.06.001. (IF=2.791, 18/79, PATHOLOGY, 2016)

9.

Liu CY, Chen KF, Chao TI, Chu PY, Huang CT, Huang TT, Yang HP, Wang WL, Lee CH, Lau KY, Tsai WC, Su JC, Wu CY, Chen MH, Shiau CW, Tseng LM*.   Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.  J Mol Med (Berl). 2017 Sep;95(9):965-975. doi: 10.1007/s00109-017-1549-x. Epub 2017 Jun 4. (IF=4.686, 18/128, MEDICINE, RESEARCH & EXPERIMENTAL, 2016)

10.

Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M.   Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.    Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. (IF=33.90, 3/217, ONCOLOGY, 2016)

11.

Sorafenib analogu e SC-60 induces apoptosis through the

SHP-1/STAT3 pathway and enhances docetaxel

cytotoxicity in triple-negative breast cancer cells

Chiu JH, Wen CS, Wang JY, Hsu CY, Tsai YF, Hung SC, Tseng LM*, Shyr YM.  Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.  J Transl Med. 2017 May 4;15(1):97. doi: 10.1186/s12967-017-1192-x. (IF=3.786, 30/128,

MEDICINE, RESEARCH & EXPERIMENTAL, 2016)

12.

Sorafenib analogu e SC-60 induces apoptosis through the

SHP-1/STAT3 pathway and enhances docetaxel

cytotoxicity in triple-negative breast cancer cells

Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z.  Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Res. 2017 Apr 11;19(1):47. (IF=5.211, 32/213, ONCOLOGY, 2015)

13.

Tseng LM*, Chiu JH, Liu CY, Tsai YF, Wang YL, Yang CW, Shyr YM.  A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women  Breast Cancer Res Treat. 2017 Jun;163(2):241-254. (IF=3.626, 82/217, ONCOLOGY, 2016)

14.

Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L.  Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2 positive breast cancer.  Breast Cancer Res. 2017 Feb 9;19(1):16  (IF=6.345, 27/217, ONCOLOGY, 2016)

15.

Liu CY, Su JC, Huang TT, Chu PY, Huang CT, Wang WL, Lee CH, Lau KY, Tsai WC, Yang HP, Shiau CW, Tseng LM*, Chen KF*.  Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.  Mol Oncol. 2017 Mar;11(3):266-279. doi: 10.1002/1878-0261.12033. Epub 2017 Feb 7. (IF=6.345, 27/217, ONCOLOGY, 2016)

16.

Liu CY, Huang TT, Huang CT, Hu MH, Wang DS, Wang WL, Tsai WC, Lee CH, Lau KY, Yang HP, Chen MH, Shiau CW, Tseng LM*, Chen KF*.  EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.  Eur J Cancer. 2017 Feb;72:112-123  (IF=6.029, 35/217, ONCOLOGY, 2016)

17.

Yeh TC, Huang TT, Yeh TS, Chen YR, Hsu KW, Yin PH, Lee HC, Tseng LM*. miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells.  PLoS One. 2016 ec;11(12):e0168171. (IF=2.806, 15/64, MULTIDISCIPLINARY SCIENCES E, 2016)

18.

Huang SM, Hsieh PL, Hsiung Y, Tseng LM, Chen PH, Hung CT  Decision-Making Process Regarding Fertility Among Reproductive-Age Women With Cancer in Taiwan.  Cancer Nurs. 2016 Oct 6.  [Epub ahead of print] . (IF=2.017, 154/213, ONCOLOGY, 2015)

19.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J   Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.  N Engl J Med. 2016 Nov 3;375(18):1738-1748. (IF=72.406, 1/155, MEDICINE, GENERAL & INTERNAL, 2016)

20.

Chen YY, Tseng LM, Yang CF, Lien PJ, Hsu CY.  Adjust cut-off values of immunohistochemistry models to predict risk of distant recurrence in invasive breast carcinoma patients.  J Chin Med Assoc.  2016 Dec;79(12):649-655. doi: 10.1016/j.jcma.2016.06.004. Epub 2016 Aug 29  (IF=1.087, 88/155, MEDICINE, GENERAL & INTERNAL, 2015)

21.

Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, Tseng LM, Lee TC, Chen KF, Liu CY, Chiu HC, Shiau CW.  Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Sci Rep. 2016 Jul 1;6:28888.  (IF=5.228, 7/63, MULTIDISCIPLINARY SCIENCES, 2015)

22.

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P.  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800  (IF=26.509, 3/213, ONCOLOGY, 2015)

23.

André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H2, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D.  Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.   J Clin Oncol. 2016 Jun 20;34(18):2115-24  (IF=20.982, 5/213, ONCOLOGY, 2015)

24.

Hsu CC, Tseng LM, Lee HC.  Role of mitochondrial dysfunction in cancer progression  Exp Biol Med (Maywood). 2016 Jun;241(12):1281-95.  (IF=2.542, 57/124, MEDICINE, GENERAL & INTERNAL, 2015)

25.

Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM*, Chen KF*.  Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget. 2016 Feb 23;7(8):9135-49 (I F=5.008；R/C=36/213，Oncology，2016)

26.

Huang SM, Tseng LM*, Chien LY, Tai CJ, Chen PH, Hung CT, Hsiung Y.  Effects of non-sporting and sporting qigong on frailty and quality of life among breast cancer patients receiving chemotherapy. Eur J Oncol Nurs. 2016 Apr;21:257-65. (I F=1.826；R/C=20/116，Nursing，2016)

27.

Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai YF, Tseng LM*, Chen WS, Shyr YM.  Molecular characteristics of recurrent triple-negative breast cancer. Mol Med Rep. 2015 Nov;12(5):7326-34. doi: 10.3892/mmr.2015.4360. Epub 2015 Sep 24.  (I F=1.692；R/C=173/217，Oncology，2016)

28.

Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L.  Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.  Ann Oncol. 2015 Dec;26(12):2429-36  (IF= 9.269, P=5.164%, R/C=11/213)

29.

Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.  Mod Pathol. 2015 Sep;28(9):1185-201  doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.

30.

Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.  Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 1

31.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.  Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.  Ann Oncol. Epub  2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. (IF= 9.269, P=5.164%, R/C=11/213)

32.

Liang SY, Chao TC, Tseng LM, Tsay SL, Lin KC, Tung HH  Symptom-Management Self-efficacy Mediates the Effects of Symptom Distress on the Quality of Life Among Taiwanese Oncology Outpatients With Breast Cancer. Cancer Nurs. Epub 2015 Feb 27 Jan-Feb;39(1):67-73  doi: 10.1097/NCC.0000000000000244 (IF=2.017, 154/213, ONCOLOGY, 2015)

33.

Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL  Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clin Cancer Res.  2015 Apr 15;21(8):1851-8 Epub 2015 Feb 19  (IF=8.738, P=5.633%, R/C=12/213)  doi: 10.1158/1078-0432.CCR-14-2075.

34.

Yang MY, Chen MT, Huang PI, Wang CY, Chang YC, Yang YP, Lo WL, Sung WH, Liao YW, Lee YY, Chang YL, Tseng LM, Chen YW, Ma HI.  Nuclear Localization Signal-Enhanced Polyurethane-Short Branch Polyethylenimine-Mediated Delivery of Let-7a Inhibited Cancer Stem-Like Properties by Targeting the 3'-UTR of HMGA2 in Anaplastic Astrocytoma.  Cell Transplant. 2015;24(8):1431-50. doi: 10.3727/096368914X682107. Epub 2014 Jun 3.

35.

Wu YT, Chen ST, Chen CJ, Kuo YL, Tseng LM, Chen DR, Kuo SJ, Lai HW. Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy. World J Surg Oncol. 2014 Nov 10;12(1):335(I F=1.20)

36.

Chou HP, Tseng LM  Outcome of mammography screening in Taiwan  J Chin Med Assoc. 2014 Oct;77(10):503-4

37.

Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM*, Chen KF*.  Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A dependent phospho-Akt inactivation in estrogen-receptor negative human breast cancer cells. Breast Cancer Res. 2014 Sep 17;16(5):431. (IF=6.345, 27/217, ONCOLOGY, 2016)

38.

Liang SY, Wu SF, Chao TC, Tseng LM, Wu WW, Wang TJ, Lu YY. The Impact of Pain on the Quality of Life of Taiwanese Oncology Patients. Pain Manag Nurs. 2014 Sep 3. pii: S1524-9042(14)00093-9. (I F=1.787)

39

Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang F, Kuo WH, Chang KJ, Lin YC, Tseng LM*, Hou MF. EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid. In Vivo. 2014 09-10;28(5):1001-1004  (I F=2.263, R/C=107/128, MEDICINE, RESEARCH & EXPERIMENTAL, 2016 )

40

Noomhorm N, Chang CJ, Wen CS, Wang JY, Chen JL, Tseng LM, Chen WS, Chiu JH, Shyr YM In vitro and in vivo effects of xanthorrhizol on human breast cancer mcf-7 cells treated with tamoxifen. J Pharmacol Sci. 2014;125(4):375-85  (I F=3.007；R/C=76/254，Pharmacology & Pharmacy)

41

Chiu JH, Chang CJ, Wu JC, Liu HJ, Wen CS, Hsu CH, Chen JL, Tseng LM*, Chen WS, Shyr YM. Screening to identify Commonly Used Chinese Herbs that affect ERBB2 and ESR1 Gene Expression using the Human Breast Cancer MCF-7 Cell Line. Evidence-Based Complementary and Alternative Medicine Epub 2014 May 27 (I F=1.740；R/C=10/26，INTEGRATIVE & COMPLEMENTARY MEDICINE，2016)

42

Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF.  Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.  Breast Cancer Res Treat. 2014 Jul;146(1):71-84. (IF=4.085, 57/213, ONCOLOGY, 2015)

43

Fu CH, Lin RJ, Yu J, Chang WW, Liao GS, Chang WY, Tseng LM, Tsai YF, Yu JC, Yu AL  A novel oncogenic role of inositol phosphatase SHIP2 in ER-Negative breast cancer stem cells: Involvement of JNK/Vimentin activation.  Stem Cells. 2014 May 6. doi: 10.1002/stem.1735

44

Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, Tai LC, King KL, Chao TC, Chiu JH, Su CH, Lo SS, Tzeng CH, Shyr YM, Tseng LM*  Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients.  PLoS ONE 9(2): e89389  (IF=2.806, 15/64, MULTIDISCIPLINARY SCIENCES E, 2016)

45

Chen JL, Chang CJ, Wang JY, Wen CS, Tseng LM, Chang WC, Noomhorm N, Liu HJ, Chen WS, Chiu JH, Shyr YM In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.  Integr Cancer Ther. 2014 Feb 12;13(3):226-239. (I F=2.354；R/C=4/22 in Integrative & Complementary Medicine | 108/196 in Oncology)